Using a mobile app to track blood sugar in pregnant women with diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a mobile app compared to traditional paper logs for monitoring blood sugar levels in pregnant women diagnosed with type 2 diabetes or gestational diabetes. Participants will record their blood sugar values four times daily, and the study aims to assess compliance and the percentage of readings within the target range. Women will be recruited from obstetric clinics at Augusta University, and the OneTouch Reveal application will be utilized for the mobile tracking. The goal is to determine if the app improves adherence to blood sugar monitoring compared to paper logs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years and older
* Verified intrauterine pregnancy
* At least 12 weeks gestation
* Diagnosed with either type 2 diabetes mellitus or gestational diabetes mellitus.

Exclusion Criteria:

* Patients with less than 4 weeks anticipated to be remaining in pregnancy
* Pre-existing use of a continuous glucose monitor or other mobile application for glucose tracking
* Type 1 diabetes mellitus
* Non-English speaking patients

Where it's running

• Augusta University
  Augusta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Rebecca Keipper, MD — Augusta University
• Study coordinator: Rebecca Keipper, MD
• Email: rkeipper@augusta.edu
• Phone: 7067212541

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.